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Objective. To investigate the possible association of calcium and vitamin D deﬁciency with hypoadiponectinemia in women
with PCOS. Subjects and Methods. In this case-control study, 103 PCOS cases and 103 controls included. The concentrations
of calcium, 25-OH-vitamin D (25OHD), adiponectin, insulin, glucose, total cholesterol, HDL-cholesterol, triglyceride (TG), and
androgens were measured in fasting blood samples. Results. Adiponectin (8.4±2.7ng/mLversus13.6±5ng/mL in control group,
P :0 .00), calcium (2 ± 0.1mmol/L versus 2.55 ± 0.17mmol/L in controls, P :0 .00), and 25-OH-Vit D (30 ± 2.99nmol/L
versus 43.7 ± 5.2nmol/L in control group, P :0 .00) levels were decreased in women with PCOS. Subjects with PCOS had higher
concentrations of TG (1.4 ± 0.77mmol/L versus 1.18 ± 0.75mmol/L in control group, P :0 .019) and dehydroepiandrosterone
sulfate (DHEA-S) (10.7 ± 11mmol/L versus 9.7 ± 10.4, P :0 .02 in control group). There were signiﬁcant correlations between
adiponectin concentrations with calcium (r :0 .78, P :0 .00) and 25OHD levels (r :0 .82, P :0 .00). The association of
hypoadiponectinemiaandPCOSwasnotsigniﬁcantconsidering25OHDasaconfoundingfactor.Conclusion.Thepresentﬁndings
indicate that the association of hypoadiponectinemia with PCOS is dependent on vitamin D. A possible beneﬁciary eﬀect of
vitamin D on the metabolic parameters in PCOS may be suggested.
1.Introduction
Obesity, insulin resistance, and type 2 diabetes are increas-
ingly prevalent worldwide [1], and adipocyte secretory
proteins (adipokines) are associated with the development of
insulin resistance. Adiponectin is a major adipokine [2], and
low levels of adiponectin are linked to diabetes, insulin resis-
tance,coronaryheartdisease,andmetabolicsyndrome[3,4].
On the other hand, alterations in vitamin D metabolism
and parathyroid hormone (PTH) concentrations are closely
related to obesity as well as the clinical aspects of the met-
abolic syndrome. Despite a larger total surface area to expose
to sunlight to produce more vitamin D in obesity, some
studies have revealed decreased concentrations of 25OHD
in obesity [5–7]. Lower mobility and consequently less ex-
posure to solar ultraviolet radiation may be a possible ex-
planation for the increased risk of relative vitamin D de-
ﬁciency in obesity [8].
Calcium ions engage in regulation of various physiologi-
calprocessesincludingmusclecontraction,celladhesion,cell
division and growth, ion transport, protein folding, protein
degradation, gene transcription, apoptosis, and exocytosis
[9]. In addition, a number of proteins, such as members of
the S100 family of calcium binding proteins, are known to
formhigherorderoligomersinacalcium-dependentmanner
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Adiponectin isoforms secreted from adipose tissue and
adipocytesfollowingcalciumchelationoradditionhavebeen
investigated. In all cases, calcium chelators reduced the level
of HMW isoforms, while the addition of calcium increased
formation of HMW adiponectin [12].
Polycystic ovary syndrome (PCOS) is characterized by
chronic anovulation and hyperandrogenism [9–11]. PCOS
can be considered as the most frequent cause of anovulation
[13] and is a prevalent endocrine disorder among women
[14]. Insulin resistance with compensatory hyperinsuli-
naemia and low adiponectin concentrations independent of
BMI has been reported in PCOS [15]. However, calcium
and vitamin D concentrations in women with PCOS and
their relationship with adiponectin have not been thor-
oughly studied. We therefore designed the present study
to investigate (a) the relationship between serum 25OHD,
calcium, and adiponectin concentrations in PCOS and (b)
the possible associations of the above elements with the
hormonal and metabolic characteristics of the syndrome.
2.SubjectsandMethods
2.1. Subjects. A total of 206 women, aged between 15 and
40 years, including 103 newly diagnosed PCOS cases and
103 healthy controls were enrolled serially in the study. All
the patients were outpatients at the Endocrine Clinic of
Vali-e-asr Hospital of Zanjan University of medical sciences
and diagnosed as PCOS based on the Rotterdam criteria
[16]. All the subjects with secondary causes of PCOS such
as prolactinoma, congenital adrenal hyperplasia, cushing
syndrome, and virilizing ovarian or adrenal tumors were
excluded. Control subjects were from the same socioeco-
nomic population who were matched for their age and
body mass index (BMI) with the cases. All women in
control group had normal ovulating cycles and no signs
of hyperandrogenism. None of the women had either any
systemic disease or use of any medication that might aﬀect
their reproductive physiology.
Approval was obtained from the ethics committee of
Zanjan University of Medical Sciences. All the participants
were notiﬁed about the goals of the study, and informed
consent was obtained. There was no cost to the participants
for the biochemical tests, and the results of these measures
were reported to them.
2.2.Measurements. Bodyweightwasmeasuredtothenearest
0.1kg with a balanced-beam scale while wearing light
clothing, and height was measured with a stadiometer
to the nearest 0.5cm. BMI was calculated based on the
weight/(height)2 formula. Waist circumferences between the
lowest rib and the iliac crest, at the level of umbilicus, were
measuredinduplicatetothenearestmillimeterusingﬂexible
tape.
In all the women, blood samples were collected between
days 3 and 6 of a spontaneous menstrual cycle, at 08-
09Am, after an at least 12 hours fast. The basal levels of LH,
FSH, testosterone, dehydroepiandrosterone sulfate(DHEA-
S), adiponectin, Insulin, plasma glucose, total calcium,
25OHDandlipidproﬁleweremeasured.Homeostasismodel
assessment index (HOMA Index) was used to determine the








Insulin resistance was considered as HOMA index more
than 2.1 [18]. Insulin, LH, FSH, and testosterone levels
were measured with electrochemiluminescence immunoas-
say (ECLIA) using commercial kits (DRG, Germany) and
adiponectin with ELISA using highly sensitive kits (Bioven-
dor,Germany,no.RD191023100).Thesensitivityoftheassay
was 0.5ng/mL, and its assay range was 1–150ng/mL. Serum
calcium levels were determined by spectrophotometer, and
25OHD was measured using ELISA (DRG, Germany). The
sensitivity of the assay was 2nmol/L, and its assay range
was 6.4–250nmol/L. Vitamin D deﬁciency was deﬁned as a
serum level of 25OHD of ≤30nmol/L and insuﬃciency as a
serum level between 30 and 75nmol/L.
2.3. Statistical Analysis. Data are presented as mean ± SD.
Statistical analysis was conducted using SPSS version 11.5.
Proportions were compared by using the Chi-square test.
Group means were compared using the Student’s t-test and
Mann-Whitney test. The Pearson correlation statistic was
used to investigate correlations between variables. Bivariate
correlation analysis (calculation of the Pearson coeﬃcient)
was used to assess the correlation of serum adiponectin,
calcium, and vitamin D levels to each parameter. Multiple
logistic regression analyses were used to assess the indepen-
dent eﬀect of hypovitaminosis D and low calcium levels on
the odds for PCOS after adjustment for confounding factors.
Independent relationships between serum adiponectin levels
and those parameters to which they were found to correlate
signiﬁcantly were assessed using multiple linear regression
models. Statistical signiﬁcance was set at P<0.05.
3. Results
The anthropometric, hormonal, and metabolic features of
the women are studied, and their statistical signiﬁcance are
summarized in Table 1.
Although PCOS was associated with higher DHEA-S
concentrations, no signiﬁcant diﬀerence was seen for testos-
terone concentrations between the two groups. LH was sig-
niﬁcantly higher in the subjects with PCOS.
Table 2 shows the mean value for calcium, vitamin D,
and adiponectin in the two groups. Subjects with PCOS
had lower calcium and 25OHD concentrations. Using logis-
tic regression analysis, lower concentration of calcium and
v i t a m i nDc a nb es e e ni nP C O Se v e na f t e ra d j u s t m e n tf o r
other confounding factors (Tables 3(a) and 3(b)).
Furthermore PCOS had a signiﬁcant negative eﬀect on
adiponectin concentrations independent of BMI and waist
circumference. The risk of having PCOS was signiﬁcantly
higher for those with lower concentrations of adiponectin
(OR: 0.6, P<0.001). This risk estimation remained sig-
niﬁcantly positive after adjustment for calcium (OR: 2.3,ISRN Endocrinology 3
Table 1: Biochemical indexes and clinical characteristics of the




(n : 103) P value
Age (year) 24.8 ± 5.6 26.4 ± 60 . 4
BMI (kg/m2) 27.7 ± 5 26.2 ± 5.2 0.9
FPG (mmol/L) 4.6 ± 0.94 4.6 ± 0.5 0.8
Chol (mmol/L) 4.3 ± 0.85 4.2 ± 0.95 0.4
TG (mmol/L) 1.4 ± 0.77 1.18 ± 0.75 0.019
HDL Chol (mmol/L) 1.23 ± 0.3 1.2 ± 0.23 0.2
LH (IU/L) 14.4 ± 12 9.2 ± 8.5 <0.001
FSH (IU/L) 8.1 ±1.49 . 3 ± 2.9 0.7
LH/FSH 2. 6 ± 21 . 6 ± 1 0.001
Testosterone (nmol/L) 0.023 ± 0.01 0.016 ± 0.01 0.07
DHEA-S (nmol/L) 10.7 ± 11 9.7 ± 10.4 0.02
BMI: body mass index; FPG: fasting plasma glucose; Chol: cholesterol;
TG: triglyceride; HDL: high density lipoprotein; FSH: follicle-stimulating
hormone; LH: luteinizing hormone.
Table 2: Mean (SD) 25OHD, calcium, adiponectin, and insulin




(n : 103) P value
Insulin (pmol/L) 80.5 ± 62.5 53.4 ± 29.8 0.004
HOMA index 2.3 ± 1.9 1.5 ± 0.9 0.007
Adiponectin (ng/mL) 8.4 ± 2.7 13.6 ± 5 <0.001
Calcium (mmol/L) 2 ± 0.1 2.55 ± 0.17 <0.001
25OHD (nmol/L) 30 ± 2.99 43.7 ± 5.2 <0.001
HOMA index: homeostasis model assessment index; 25OHD: 25 hydroxy
vitamin D.
P :0 .04). After adjustment for vitamin D concentration,
noassociationwasfoundbetweenhypoadiponectinemiaand
PCOS (Table 4).
A signiﬁcant negative correlation was seen in the par-
ticipants between adiponectin and insulin (r : −0.24, P :
0.009) even after adjustment for BMI. Adiponectin was
correlate potently to calcium (r :0 .8, P<0.001) and
25OHD (r :0 .83, P<0.001) in the both groups of the
participants. Thirty-eight people of the participants (21.6%)
are recognized to have vitamin D deﬁciency, and 99 subjects
(56%) had vitamin D insuﬃciency. In comparison to those
with vitamin-D suﬃcient status, these people had higher
waist circumference (87 ± 12cm versus 82.3±13.7cmresp.,
P :0 .04), BMI (29 ± 4.5kg/m2 versus 26.5 ± 5kg/m 2 resp.,
P :0 .008), and lower adiponectin concentration (6.7 ±
2.3ng/mL versus 12 ± 4.4ng/mL resp., P<0.001).
Although there was a signiﬁcant negative correlation
between insulin, calcium (r : −0.29, P :0 .001), and 25OHD
(r : −.29, P : 002), these correlations were not signiﬁcant
after adjustment for BMI and waist circumference (Table 5).
There was a signiﬁcant correlation between triglyceride
concentration and calcium (r : −0.2, P :0 .02) but
not with vitamin D (P :0 .09). We did not ﬁnd any
Table 3: (a) Logistic regression analyses of vitamin D and other
confounding variables to predict PCOS, (b) Logistic regression






variables Odds ratio CI (95%) P value
25OHD 1.6 1.23–1.97 <0.001
Age 0.9 0.8–1 0.9
PCOS WC 0.89 0.79–1.01 0.2
BMI 1.16 0.89–1.43 0.5
Insulin
concentration 1.02 0.89–1.15 0.8
25OHD: 25 hydroxy vitamin D; PCOS: polycystic ovary syndrome; WC:





variables Odds ratio CI (95%) P value
PCOS
Calcium 4.2 3.1–5.3 <0.001
Adiponectin 2.3 1.88–2.7 0.04
Age 1.01 0.91–1.11 0.8
WC 1 0.92–1.08 0.9
BMI 0.87 0.62–1.12 0.6
Insulin
concentration 1.04 0.98–1.08 0.3
PCOS: polycystic ovary syndrome; WC: waist circumference; BMI: body
mass index.
Table 4: Logistic regression analyses of adiponectin to predict




variables Odds ratio CI (95%) P value
Adiponectin 0.7 0.33–1.07 0.06
Age 0.9 0.8–1.1 0.9
PCOS WC 0.86 0.74–1.01 0.2
BMI 1.4 1–1.8 0.3
25OHD 1.9 1.3–2.5 0.002
25OHD: 25 Hydroxy vitamin D; PCOS: Poly Cystic Ovary Syndrome; WC:
Waist circumference; BMI: Body Mass Index.
Table 5: Multiple linear regression analyses of association between




Variables Odds ratio CI (95%) P-value
25OHD
Insulin 1.1 0.95–1.05 0.2
Age 1.8 0.8–1.1 0.06
WC 1.3 0.98–1.15 0.1
BMI 1.3 0.99–1.5 0.9
25OHD: 25 hydroxy vitamin D; PCOS: polycystic ovary syndrome; WC:
waist circumference; BMI: body mass index.
correlations between calcium or vitamin D and cholesterol,
HDL cholesterol or fasting plasma glucose concentrations.4 ISRN Endocrinology
Table 6: Diﬀerences in calcium and 25OHD in the subjects with and without PCOS based on their BMI.
Parameter











(n = 16) P
Calcium (mmol/L) 2.07 ± 0.1 2.02 ± 0.17 1.9 ± 0.1 0.2 2.6 ± 0.15 2.5 ± 0.15 2.37 ±
0.15 0.003
25OHD (nmol/L) 31.2 ± 2.49 30.9 ± 4.7 28.9 ± 2.9 0.03 43.7 ± 3.7 43.9 ± 5.2 39.4 ± 2.9 0.02
Not only PCOS but also increased body weight had a
signiﬁcant negative eﬀect on serum calcium and 25OHD
concentrations.Speciﬁcally,obesewomeninthebothgroups
(PCOS and their controls) had signiﬁcantly lower vitamin D
concentrations than did normal-weight women (P = 0.03)
(Table 6).
4. Discussion
This study determined signiﬁcantly lower concentrations
of calcium, vitamin D, and adiponectin in subjects with
PCOS independent to BMI. Furthermore, a potent positive
relationship was found between calcium, 25OHD, and
adiponectin concentrations. This study revealed that the
correlation between lower concentrations of calcium and
vitamin D with insulin resistance is dependent to BMI and
waist circumference in PCOS. We found that the association
ofhypoadiponectinemiawithPCOSisdependentonvitamin
D. To the best of our knowledge, this is the ﬁrst study in
which the possible role of calcium and vitamin D on the
hypoadiponectinemia in a sizeable sample of women with
PCOS and their controls was investigated.
Obese women in the both groups had signiﬁcantly lower
calcium and vitamin D concentrations than normal-weight
women in this study. These ﬁndings are in agreement with
previous reports of decreased calcium and vitamin D con-
centrations in obese, compared with normal-weight patients
[5, 6, 19, 20].
Decreased vitamin D concentrations have been reported
in some diseases including type 2 diabetes mellitus (T2DM),
obesity, and hypertension [21]. Furthermore, the presence of
v i t a m i nDr e c e p t o r si ns e v e r a lt i s s u e ss u c ha sp a n c r e a t i cb e t a
cells, adipocyte, and muscle cells suppose, a potent role of
this vitamin in the regulation of metabolism of the body. In
obese individuals, the impaired vitamin D endocrine system
could act on renin-angiotensin system and also in vascular
function and induce hypertension [22]. In pancreatic cells,
impaired vitamin D actions may contribute to higher
intracellular calcium, which makes less insulin secretion.
Deterioration of insulin action in peripheral tissues also has
beenreportedinvitaminDdeﬁciency.Somestudiesreported
more important role of PTH than vitamin D in obesity and
metabolic syndrome [23]. Although we did not measure
PTH in our study, there are some studies reported higher
concentrations of PTH in PCOS [24].
In the present study, women with PCOS had signiﬁcantly
lower calcium and 25OHD concentrations than ovulatory
normalwomen.Thisdiﬀerenceremainedsigniﬁcantforboth
groups after adjustment for BMI. Although lower calcium
and 25OHD concentrations in PCOS have been reported
previously [25–27], some reports indicated that this reduced
levels may result from the presence of obesity and insulin
resistance rather than PCOS per se [26, 27]. Regarding the
results of the present study, hypovitaminosis D possibly is
linked to PCOS and vitamin D supplements may be eﬀective
in prevention of PCOS.
Interestingly, we found that hypoadiponectinemia in
PCOS is dependent on vitamin D deﬁciency. Regarding on
a conﬁrmed association of low adiponectin concentration
in PCOS and its relation to insulin resistance independent
of BMI [15], a good explanation for the above ﬁndings
wouldbethathypoadiponectinemiamaybeduetodecreased
concentrations of vitamin D metabolites.
A signiﬁcant negative correlation between calcium (and
vitaminDwithaborderlineP valueof0.09)withtriglyceride
concentrations and not cholesterol and plasma glucose
was also observed, in agreement with previous reports
of a positive association between hypovitaminosis D and
metabolic abnormalities in PCOS [28].
Although some data are available for the eﬀect of vitamin
D[ 29] or calcium supplementation [30]o nm e t a b o l i c
indexes in obese subjects, there are little intervention trials
to evaluate the eﬀect of vitamin D supplementation on
metabolic disturbances in PCOS women. One of them has
been published in 2009 and showed a signiﬁcantly increased
secretionoftheﬁrstphaseofinsulinsecretionaftertreatment
withalphacalcidol.Afavorablestatisticallysigniﬁcantchange
also was observed in the lipid proﬁle [31].
In this study, subjects with PCOS had higher con-
centrations of DHEA-S than normal subjects. Elevated
levels of DHEA-S have been reported in 25% to 50% of
women with PCOS. The exact etiology of adrenal androgen
excessisnotknown.Increasedadrenocorticotropichormone
(ACTH) production, increased adrenal sensitivity to ACTH,
altered steroidogenic enzyme activity (17–20 lyase, 3-beta-
hydroxysteroid dehydrogenase activity), and an overproduc-
tion of androgens in response to hyperprolactinemia have all
been implicated as potential mechanisms [32].
Connection between ovarian estrogen production and
adrenal androgen synthesis has been evaluated. Estrogens
could have a direct adrenal eﬀect, or their eﬀect could be
mediatedviaprolactin.Estrogensareknowntoincreasepitu-
itary prolactin secretion, which in turn will augment adrenal
DHEAS output. The induction of hypoestrogenism with
gonadotropin-releasing hormone agonist reduces DHEAS
levels. On the other hand, some of these metabolic charac-
teristics may have a genetic background [32].ISRN Endocrinology 5
We did not ﬁnd any association between vitamin D and
androgens or gonadotropin concentrations in our study.
These ﬁndings suppose no eﬀect of vitamin D or calcium
supplementation to reduce hyperandrogenism in PCOS.
However,thereisonereportrecentlytosupportthefavorable
eﬀect of adding calcium and vitamin D to metformin
to induce ovulatory cycles in PCOS [33], but larger-scale
investigations are deﬁnitely needed to clarify this issue.
In conclusion, the results of the present study are in
agreement with previous data supporting an association of
decreased calcium and vitamin D with PCOS but do not
support the independent association of these elements with
insulin resistance.
Moreover, our ﬁndings indicate, for the ﬁrst time, that
hypovitaminosis D probably is also linked to PCOS-asso-
ciated hypoadiponectinemia by means of BMI-independent
mechanisms.
It is very possible that dietary supplementation of these
nutrients can reduce risk of subsequent development of
diabetes in the subjects with PCOS. The possible beneﬁciary
eﬀect of vitamin D on the prevention of PCOS remains to be
revealed.
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